MC
MRNA icon

Moors & Cabot’s Moderna MRNA Stock Holding History

Moors & Cabot’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
14,616
+4,700
+47% +$243K 0.04% 382
2026
Q1 		$504K Sell
9,916
-6,556
-40% -$306K 0.02% 550
2025
Q4 		$486K Sell
16,472
-3,165
-16% -$86K 0.02% 546
2025
Q3 		$507K Sell
19,637
-1,450
-7% -$40.4K 0.02% 522
2025
Q2 		$582K Buy
21,087
+800
+4% +$21.1K 0.03% 474
2025
Q1 		$575K Sell
20,287
-36,136
-64% -$1.28M 0.03% 446
2024
Q4 		$2.35M Buy
56,423
+1,954
+4% +$93.4K 0.11% 161
2024
Q3 		$3.64M Buy
54,469
+8,390
+18% +$770K 0.18% 110
2024
Q2 		$5.47M Buy
46,079
+110
+0.2% +$13.9K 0.29% 72
2024
Q1 		$4.9M Buy
45,969
+5,919
+15% +$597K 0.27% 86
2023
Q4 		$3.98M Buy
40,050
+12,149
+44% +$1.02M 0.25% 90
2023
Q3 		$2.88M Sell
27,901
-7,007
-20% -$782K 0.2% 115
2023
Q2 		$4.24M Sell
34,908
-1,139
-3% -$152K 0.28% 84
2023
Q1 		$5.54M Sell
36,047
-271
-0.7% -$44.7K 0.38% 55
2022
Q4 		$6.52M Sell
36,318
-505
-1% -$82.6K 0.45% 42
2022
Q3 		$4.35M Sell
36,823
-314
-0.8% -$47.6K 0.33% 73
2022
Q2 		$5.3M Buy
37,137
+334
+0.9% +$47.7K 0.38% 57
2022
Q1 		$6.34M Sell
36,803
-1,220
-3% -$205K 0.39% 56
2021
Q4 		$9.66M Sell
38,023
-1,070
-3% -$313K 0.59% 33
2021
Q3 		$15M Sell
39,093
-6,731
-15% -$2.48M 0.94% 18
2021
Q2 		$10.8M Sell
45,824
-408
-0.9% -$72.9K 0.76% 19
2021
Q1 		$6.05M Buy
46,232
+546
+1% +$79.1K 0.46% 50
2020
Q4 		$4.77M Buy
45,686
+315
+0.7% +$31.9K 0.4% 59
2020
Q3 		$3.21M Sell
45,371
-3,810
-8% -$266K 0.3% 80
2020
Q2 		$3.15M Sell
49,181
-13,438
-21% -$736K 0.34% 72
2020
Q1 		$1.88M Buy
62,619
+13,000
+26% +$299K 0.27% 88
2019
Q4 		$980K Buy
49,619
+9,900
+25% +$176K 0.1% 213
2019
Q3 		$632K Buy
39,719
+8,200
+26% +$121K 0.07% 273
2019
Q2 		$456K Buy
+31,519
New +$677K 0.06% 318

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Moors & Cabot's MRNA Position: Q2 2026 in Review

Moors & Cabot increased its Moderna (MRNA) stake by 47% in Q2 2026, buying an estimated $243K and bringing the position to 14,616 shares worth $1.02M. The position accounts for 0.04% of the portfolio, ranked #382.

Moors & Cabot first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $15M in Q3 2021. 424 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Moors & Cabot held 14,616 shares of Moderna worth $1.02M as of Q2 2026.
  • Moors & Cabot bought 4,700 Moderna shares in Q2 2026, an estimated $243K.
  • Moderna made up 0.04% of Moors & Cabot's portfolio in Q2 2026, its #382 holding.
  • Moors & Cabot first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Moors & Cabot's Moderna position peaked at $15M in Q3 2021.
  • 424 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.